Predicta Biosciences Secures $5.2 Million in Seed Funding to Revolutionize Precision Oncology with Multiomics and Liquid Biopsies

Predicta Biosciences, a precision oncology company revolutionizing diagnostic and therapeutic products with cutting-edge multiomics and liquid biopsies, has successfully raised $5.2 million in funding. The company's innovative diagnostic product portfolio aims to improve treatment decision-making for immunotherapies by offering a non-invasive alternative to bone-marrow biopsies through small blood-based samples. This recent funding will further support Predicta's mission to advance their in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development, ultimately enhancing the landscape of precision medicine in oncology. The investment will enable Predicta Biosciences to continue driving innovation in the field of oncology and bring much-needed advancements to patient care and treatment strategies.